---
title: HLD
layout: diseases
author: Corbin Cox
last-updated: 2018-12-23
created: 2018-12-23
toc: true
common: false
---
# Dx[^grundy2018]<sup>, </sup>[^jacobson2015]

$$
\text{LDL-C} = \text{TC} - \frac{\text{TG}}{5}-\text{HDL}
$$

Calculation is inaccurate if LDL &lt; 70, and adjustments exist in that circumstance.

Normal Labs
{: .caption}

| Lab     | Normal   | Abnormal                           |
| ------- | -------- | ---------------------------------- |
| TG      | &lt; 150 | &ge; 200                           |
| HDL     |          | &lt; 40 (men)<br />&lt; 50 (women) |
| LDL     | &lt; 100 | &ge; 160                           |
| Non-HDL | &lt; 130 | &ge; 190                           |




# Tx[^grundy2018]

Statin Classification
{: .caption}

| Low                    | Medium                             | High                   |
| ---------------------- | ---------------------------------- | ---------------------- |
| &lt; 30% LDL reduction | 30-49& LDL reduction               | &ge; 50% LDL reduction |
| Simvastatin 10mg       | Atorvastatin 10-20mg               | Atorvastatin 40-80mg   |
| Pravastatin 10-20mg    | Rosuvastatin 5-10mg                | Rosuvastatin 20-40mg   |
| Lovastatin 20mg        | Simvastatin 20-40mg                |                        |
| Fluvastatin 20-40mg    | Pravastatin 40mg                   |                        |
|                        | Lovastatin 40mg                    |                        |
|                        | Fluvastatin 40mg BID or 80mg XL QD |                        |
|                        | Pitavastatin 1-4mg                 |                        |

## Statin Initiation

* Pt has Clinical ASCVD
  * Stratify based on risk
  * Clinical ASCVD: ACS, Hx of MI, Stroke, TIA, PAD
  * Major Events
    * ACS w/i 12mo
    * Hx of MI
    * Hx of ischemic stroke
    * Symptomatic PAD
  * High-risk Conditions
    * &ge; 65yo
    * Familial hypercholesterolemia
    * Prior CABG or PCI
    * DM
    * HTN
    * eGFR &lt; 60
    * Smoker
    * LDL &ge; 100 despite maximal statin therapy
    * CHF
* Very High ASCVD Risk
  * Multiple ASCVD events or 1 major event w/ multiple high-risk conditions
  * High-intensity statin
  * Add ezetimibe if LDL &ge; 70
  * Add PCSK9 if LDL &ge; 70 or non-LDL &ge; 100 w/ ezetimibe and statin
* All other risk stratification
  * &gt; 75 yo: Consider moderate or high-intensity statin as tolerated
  * &le; 75 yo: High intensity statin, followed by ezetimibe if LDL-C &ge; 70
* All DM pts 40-75yo receive moderate intensity, if not higher
* All pts 20-75yo w/ LDL &ge; 190 receive high-intensity
* ASCVD Risk &ge; 7.5% w/ other risk factor or &ge; 20% get high intensity statin
* All pts 40-75 w/ LDL 70-189 receive intermediate statin
* Use lower intensity statins if high-intensity not tolerated

## Statin Adjustment

**NLA Risk Stratification**

* Low
  * 0-1 major ASCVD risk factors
* Moderate
  * 2 major ASCVD risk factors
* High
  * &ge; 3 major ASCVD risk factors
  * DM
  * CKD 3B or 4
  * LDL &ge; 190
  * &ge; 15% ASCVD 10-Year Risk
* Very High
  * ASCVD
  * DM w/ &ge; 2 other risk factors or end organ damage
* Major Risk Factor
  * M &ge; 45yo or F &ge; 55yo
  * FHx of Early CHD
    * &lt; 55yo for M relatives
    * &lt; 65yo for F relatives
  * Current Smoker
  * BP &ge; 140/90 or currently on BP meds
  * HDL &lt; 40 (M) or &lt; 50 (F)

Treatment Goals
{: .caption}

| Risk Category | Non-HDL  | LDL      | Apo B   |
| ------------- | -------- | -------- | ------- |
| Low           | &lt; 130 | &lt; 100 | &lt; 90 |
| Moderate      | &lt; 130 | &lt; 100 | &lt; 90 |
| High          | &lt; 130 | &lt; 100 | &lt; 90 |
| Very High     | &lt; 130 | &lt; 70  | &lt; 80 |

**See NLA Part 2 for Special Population Management (Jentzer 2015)**[^jentzer2015]

## Misc Drug Therapies

| Drug                              | &Delta;LDL           | &Delta;Non-HDL      | &Delta;HDL         | &Delta;TG     |
| --------------------------------- | -------------------- | ------------------- | ------------------ | ------------- |
| BAS                               | &darr; 15-30%        | &darr; 4-16%        | &uarr; 3-5%        | &uarr; 0-10%  |
| Nicotinic Acid                    | &darr; 5-25%         | &darr; 8-23%        | &uarr; 15-35%      | &darr; 20-50% |
| Fibrates                          | &darr; 5- &uarr; 20% | &darr; 5-19%        | &uarr; 10-20%      | &darr; 20-50% |
| Omega-3s                          | &darr; 6-&uarr; 25%  | &darr; 5-&uarr; 14% | &darr; 5-&uarr; 7% | &darr; 19-44% |
| Cholesterol Absorption Inhibitors | &darr; 13-20%        | &darr; 14-19%       | &uarr; 3-5%        | &darr; 5-11%  |

**Do not use fibrates with statins**

# References

[^grundy2018]: Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Journal of the American College of Cardiology*. November 2018. doi:[10.1016/j.jacc.2018.11.003](https://doi.org/10.1016/j.jacc.2018.11.003)

[^jacobson2015]: Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. *Journal of Clinical Lipidology*. 2015;9(2):129-169. doi:[10.1016/j.jacl.2015.02.003](https://doi.org/10.1016/j.jacl.2015.02.003)

[^jentzer2015]: Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2015;20(3):249-260. doi:[10.1177/1074248414559838](https://doi.org/10.1177/1074248414559838)